| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
146,000,000 |
| Market
Cap: |
19.31(B) |
| Last
Volume: |
1,621,262 |
Avg
Vol: |
1,396,245 |
| 52
Week Range: |
$92.79 - $147.2 |
|
| Level
I Sector: |
Information Technology |
| Level
II Sector: |
Electronics |
| Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 509 |
| Guru Rank Value : 3.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
7,330 |
7,330 |
| Total Buy Value |
$0 |
$0 |
$991,672 |
$991,672 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
315 |
22,201 |
| Total Sell Value |
$0 |
$0 |
$35,545 |
$4,541,175 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
16 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ronaghi Mostafa |
Sr VP & CTO |
• • – |
2017-01-30 |
4 |
D |
$159.28 |
$106,877 |
D/D |
(671) |
60,746 |
|
- |
|
| Stapley Marc |
EVP & Chief Administrative Ofc |
• • – |
2017-01-30 |
4 |
D |
$159.28 |
$126,628 |
D/D |
(795) |
35,750 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2017-01-30 |
4 |
AS |
$160.90 |
$41,673 |
D/D |
(259) |
27,690 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2017-01-30 |
4 |
D |
$159.28 |
$113,567 |
D/D |
(713) |
27,949 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2017-01-30 |
4 |
D |
$159.28 |
$443,436 |
D/D |
(2,784) |
498,453 |
|
- |
|
| Henry Christian O |
EVP & Chief Commercial Officer |
• • – |
2017-01-30 |
4 |
D |
$159.28 |
$126,628 |
D/D |
(795) |
17,531 |
|
- |
|
| Dadswell Charles |
Sr VP & General Counsel |
• • – |
2017-01-30 |
4 |
D |
$159.28 |
$40,776 |
D/D |
(256) |
8,164 |
|
- |
|
| Bouchard Michel |
Chief Accounting Officer |
• • – |
2017-01-30 |
4 |
D |
$159.28 |
$127,105 |
D/D |
(798) |
22,410 |
|
- |
|
| Hampton Malcolm Garret |
EVP Clinical Genomics GroupOff |
• – – |
2017-01-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,533 |
|
- |
|
| Dorsa Caroline |
Director |
– • – |
2017-01-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,996 |
|
- |
|
| Dorsa Caroline |
Director |
• • – |
2017-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,996 |
4,996 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2017-01-19 |
4 |
AS |
$160.35 |
$60,612 |
D/D |
(378) |
28,662 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2017-01-17 |
4 |
AS |
$160.00 |
$320,000 |
D/D |
(2,000) |
29,040 |
|
- |
|
| Bowman A Blaine |
Director |
• • – |
2017-01-11 |
4 |
AS |
$160.67 |
$488,658 |
D/D |
(3,000) |
15,704 |
|
- |
|
| Bowman A Blaine |
Director |
• • – |
2017-01-11 |
4 |
OE |
$42.82 |
$128,460 |
D/D |
3,000 |
18,704 |
|
- |
|
| Dadswell Charles |
Sr VP & General Counsel |
• • – |
2017-01-10 |
4 |
AS |
$161.60 |
$18,746 |
D/D |
(116) |
8,420 |
|
- |
|
| Samad Samer Abdul |
Sr. VP and CFO |
• • – |
2017-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,209 |
2,209 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2017-01-04 |
4 |
AS |
$133.93 |
$81,008 |
D/D |
(600) |
16,465 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2017-01-04 |
4 |
OE |
$71.09 |
$42,654 |
D/D |
600 |
17,065 |
|
- |
|
| Desouza Francis A |
President and CEO |
• • – |
2016-12-16 |
4 |
D |
$131.01 |
$253,897 |
D/D |
(1,938) |
117,205 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2016-12-15 |
4 |
AS |
$126.16 |
$252,320 |
D/D |
(2,000) |
31,040 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2016-12-12 |
4 |
AS |
$122.31 |
$74,054 |
D/D |
(600) |
16,465 |
|
- |
|
| Bradbury Daniel |
Director |
• • – |
2016-12-12 |
4 |
OE |
$71.09 |
$42,654 |
D/D |
600 |
17,065 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2016-12-08 |
4 |
AS |
$121.63 |
$364,890 |
D/D |
(3,000) |
52,988 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2016-12-05 |
4 |
A |
$0.00 |
$0 |
D/D |
15,635 |
501,237 |
|
- |
|
1655 Records found
|
|
Page 36 of 67 |
|
|
6.12 (4.85%) 
